Moacyr Ribeiro de Oliveira

Suggest Changes
Learn More
7559 Background: Inhibition of angiogenesis has clinical benefits in NSCLC. Depriving tumors of blood flow by adding bevacizumab (B) to other vasculature-directed agents has been hampered by(More)
  • 1